☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Suicide Warning on Atomoxetine

The manufacturers of Atomoxetine (Strattera) have updated the Summary of Product Characteristics to include a warning about suicide related behaviour.

Suicide related behaviour is defined as suicidal ideation or a suicide attempt. In double blind clinical trials suicide related behaviour occurred in about 0.5% of patients taking Atomoxetine, this behaviour was absent in the placebo arms of the studies.

Action: Patients (and their parents or guardians) should be made aware of this new information. Any behavioural changes including depression, suicidal ideation or suicide attempts should prompt a rapid referral for re-assessment and a change of treatment if necessary.

Share 'Suicide Warning on Atomoxetine' by emailShare 'Suicide Warning on Atomoxetine' on FacebookShare 'Suicide Warning on Atomoxetine' on TwitterShare 'Suicide Warning on Atomoxetine' on LinkedInShare 'Suicide Warning on Atomoxetine' on reddit


No Comments to “Suicide Warning on Atomoxetine”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.